Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 26, 2008 16:00 ET | Source: Eurand N.V.

FDA Issues Complete Response Letter to GlaxoSmithKline for Eurand's EUR-1048

PHILADELPHIA, Dec. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
December 26, 2008 16:00 ET | Source: Eurand N.V.

FDA Issues Complete Response Letter to GlaxoSmithKline for Eurand's EUR-1048

GlaxoSmithKline Responds to Complete Response Letter PHILADELPHIA, Dec. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced...
December 23, 2008 13:03 ET | Source: Eurand N.V.

Eurand's Raw Material Supplier Submits Response to FDA for DMF-Related Questions On EUR-1008 (ZENTASE(r))

PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
December 23, 2008 12:51 ET | Source: Eurand N.V.

Eurand's Raw Material Supplier Submits Response to FDA for DMF-Related Questions On EUR-1008 (ZENTASE(r))

PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
November 20, 2008 11:00 ET | Source: Eurand N.V.

Eurand Appoints Dr. Ruth Thieroff-Ekerdt as Chief Medical Officer

PHILADELPHIA, Nov. 20, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
November 11, 2008 14:11 ET | Source: Eurand N.V.

Eurand to Present At Lazard Capital Markets 5th Annual Healthcare Conference

PHILADELPHIA, Nov. 11, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
November 07, 2008 07:00 ET | Source: Eurand N.V.

Eurand Reports Recent Developments and Third Quarter and Year-to-Date 2008 Financial Results

Highlights: * Grew third quarter 2008 revenues to EUR 24.6 million ($32.0 million), a 30% increase in constant currency from the third quarter of 2007; * Grew year-to-date...
October 09, 2008 12:30 ET | Source: Eurand N.V.

Eurand Announces Conference Call On Third Quarter 2008 Financial Results

AMSTERDAM, The Netherlands, Oct. 9, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and...
September 30, 2008 09:31 ET | Source: Eurand N.V.

Eurand Provides Update On EUR-1008 (ZENTASE)

PHILADELPHIA, Sept. 30, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and...
August 26, 2008 10:37 ET | Source: Eurand N.V.

Eurand to Present At Thomas Weisel Partners Healthcare Conference 2008

PHILADELPHIA, Aug. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...